Vyvanse Dose Above 70mg for Severe ADHD
Do not exceed 70 mg of Vyvanse (lisdexamfetamine) daily, as this is the maximum FDA-approved dose with established safety and efficacy data. 1
FDA-Approved Maximum Dose
The FDA label explicitly states that Vyvanse is available in strengths up to 70 mg, and pharmacokinetic studies demonstrate linear dose-response between 30-70 mg in pediatric patients and 50-250 mg in adults 1. However, the clinical trials establishing efficacy and safety only studied doses up to 70 mg 2, 3. The research explicitly notes that "results do not provide information about doses above 70 mg/d, which is the maximum approved dose of LDX and the highest dose studied in ADHD clinical trials" 2.
Evidence for Dose-Response Relationship
While higher baseline severity may benefit from higher doses within the approved range 2, 4, the dose-response curve shows:
- All three doses (30,50,70 mg) demonstrated significant efficacy over placebo 3
- No significant differences in efficacy were found between the 50 mg and 70 mg doses 3, 5
- Greater baseline severity correlates with larger absolute symptom reduction, but this occurs within the 30-70 mg range 2, 4
The meta-analysis confirms that "differing dosages did not yield significant differences in ADHD symptom management" 5, suggesting a ceiling effect at or before 70 mg.
Alternative Strategies for Inadequate Response at 70mg
If severe ADHD symptoms persist despite optimized 70 mg Vyvanse dosing, consider these evidence-based alternatives rather than exceeding the maximum dose:
1. Switch to Alternative Stimulant
- Guidelines recommend switching from methylphenidate to lisdexamfetamine (or vice versa) when adequate response is not achieved 6
- Different stimulant mechanisms may provide better individual response
2. Add Non-Stimulant Augmentation
- Atomoxetine, guanfacine, or clonidine can be added to stimulant therapy 6
- These provide "around-the-clock" coverage and may address residual symptoms 6
3. Combination with Behavioral Therapy
- Behavioral interventions show positive effects when combined with medication 7
- May address functional impairments not fully responsive to medication alone
4. Reassess Diagnosis and Comorbidities
- Treatment-resistant symptoms may indicate comorbid conditions (anxiety, depression, substance use, sleep disorders) requiring separate management 7, 6
- Substance use screening is particularly important in adolescents and adults 7
Safety Considerations
The safety profile at 70 mg includes:
- Decreased appetite (most common)
- Insomnia
- Increased pulse and blood pressure (mean increases: pulse +7 bpm, systolic BP +3.4 mmHg, diastolic BP +3.2 mmHg) 8
- Growth effects in pediatric populations (mean weight gain only 2.1 kg over 2 years) 8
Exceeding 70 mg would enter uncharted territory without safety data, potentially increasing cardiovascular risks, psychiatric adverse events, and abuse liability without proven additional benefit.
Common Pitfalls to Avoid
- Don't assume inadequate response means insufficient dose - consider medication adherence, timing of administration, comorbidities, and psychosocial stressors first
- Don't overlook the prodrug mechanism - Lisdexamfetamine requires red blood cell hydrolysis to become active; individual variation in metabolism exists but cannot be overcome by simply increasing dose 1
- Don't ignore the controlled substance status - Vyvanse carries abuse potential despite its prodrug design; doses above 70 mg increase diversion risk without evidence of benefit 7, 9